HRP20000799A2 - Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation - Google Patents
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation Download PDFInfo
- Publication number
- HRP20000799A2 HRP20000799A2 HR20000799A HRP20000799A HRP20000799A2 HR P20000799 A2 HRP20000799 A2 HR P20000799A2 HR 20000799 A HR20000799 A HR 20000799A HR P20000799 A HRP20000799 A HR P20000799A HR P20000799 A2 HRP20000799 A2 HR P20000799A2
- Authority
- HR
- Croatia
- Prior art keywords
- pyrimido
- phenylamino
- pyrimidin
- dihydro
- methyl
- Prior art date
Links
- -1 Bicyclic pyrimidines Chemical class 0.000 title claims description 106
- 239000003112 inhibitor Substances 0.000 title description 11
- 230000004663 cell proliferation Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 141
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 57
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 19
- 150000002466 imines Chemical group 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 17
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 16
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 16
- 108091000080 Phosphotransferase Proteins 0.000 claims description 15
- 102000020233 phosphotransferase Human genes 0.000 claims description 15
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 15
- 150000003573 thiols Chemical class 0.000 claims description 15
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical class [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000001301 oxygen Chemical class 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 12
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 11
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- LPUCHTNHUHOTRY-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)ethanamine Chemical compound C1CC2C(C(N)C)CC1C2 LPUCHTNHUHOTRY-UHFFFAOYSA-N 0.000 claims description 10
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 230000033115 angiogenesis Effects 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 101150073031 cdk2 gene Proteins 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 10
- 208000037803 restenosis Diseases 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 9
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 9
- 239000004202 carbamide Substances 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 150000002829 nitrogen Chemical class 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 150000002825 nitriles Chemical class 0.000 claims description 8
- 239000011593 sulfur Chemical class 0.000 claims description 8
- 125000004001 thioalkyl group Chemical group 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 210000002464 muscle smooth vascular Anatomy 0.000 claims description 7
- 150000002923 oximes Chemical class 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 6
- JPOJBQLUJAIHHL-UHFFFAOYSA-N 1h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=CN=C2NC(=O)N=CC2=C1 JPOJBQLUJAIHHL-UHFFFAOYSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims description 6
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims description 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical class ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 5
- CKEBVRPXMIKWIP-UHFFFAOYSA-N 8-methyl-2-(4-pyrazol-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1C=CC=N1 CKEBVRPXMIKWIP-UHFFFAOYSA-N 0.000 claims description 4
- FXCWWKGXYURZGF-UHFFFAOYSA-N 8-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C)C2=N1 FXCWWKGXYURZGF-UHFFFAOYSA-N 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- NFKADCJUKLTGRB-UHFFFAOYSA-N 1-propan-2-yl-7-(4-pyrazol-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C(C)C)C2=NC=1NC(C=C1)=CC=C1N1C=CC=N1 NFKADCJUKLTGRB-UHFFFAOYSA-N 0.000 claims description 3
- AKJJXTNCIMJSTI-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-propan-2-ylpyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C(C)C)C2=NC=1NC(C=C1)=CC=C1N1CCN(C)CC1 AKJJXTNCIMJSTI-UHFFFAOYSA-N 0.000 claims description 3
- LSQGLPJPPZIBTL-UHFFFAOYSA-N 7-[4-(diethylamino)butylamino]-3-(3,5-dimethoxyphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound O=C1N(CC)C2=NC(NCCCCN(CC)CC)=NC=C2CN1C1=CC(OC)=CC(OC)=C1 LSQGLPJPPZIBTL-UHFFFAOYSA-N 0.000 claims description 3
- KQWHLVPKNZXXEV-UHFFFAOYSA-N 7-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-1-propan-2-ylpyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C(C)C)C2=NC=1NC(C=C1)=CC=C1N1CCC(N(C)C)CC1 KQWHLVPKNZXXEV-UHFFFAOYSA-N 0.000 claims description 3
- SRCVYIHSYUUCQT-UHFFFAOYSA-N 8-(3-bicyclo[2.2.1]heptanyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3C4CCC(C4)C3)C2=N1 SRCVYIHSYUUCQT-UHFFFAOYSA-N 0.000 claims description 3
- QQOUBGFAMSXQJP-UHFFFAOYSA-N 8-propan-2-yl-2-(4-pyrazol-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C(C)C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1C=CC=N1 QQOUBGFAMSXQJP-UHFFFAOYSA-N 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010057469 Vascular stenosis Diseases 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- OWTGPKDIDKXNHZ-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)-7-(4-pyrazol-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3C4CCC(C4)C3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N1C=CC=N1 OWTGPKDIDKXNHZ-UHFFFAOYSA-N 0.000 claims description 2
- CXCVAMWLZIFURV-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)-7-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3C4CCC(C4)C3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 CXCVAMWLZIFURV-UHFFFAOYSA-N 0.000 claims description 2
- WVONWGTWBWLAOJ-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)-7-[4-[4-(dimethylamino)piperidin-1-yl]anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1CC(N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C3C4CCC(C4)C3)C2=N1 WVONWGTWBWLAOJ-UHFFFAOYSA-N 0.000 claims description 2
- WALFZDZPONVUIH-UHFFFAOYSA-N 1-(3-hydroxypropyl)-7-[4-(4-methylpiperazin-1-yl)anilino]pyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2CCCO WALFZDZPONVUIH-UHFFFAOYSA-N 0.000 claims description 2
- FOTIWFNYARKEJV-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5,8-dihydropyrimido[4,5-d]pyrimidin-7-yl]-3-propan-2-ylurea Chemical compound N=1C=C2CNC(NC(=O)NC(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 FOTIWFNYARKEJV-UHFFFAOYSA-N 0.000 claims description 2
- JMNNHVDOWHBZGS-UHFFFAOYSA-N 1-[3-(2-chloro-3,5-dimethoxyphenyl)-7-[4-[2-(diethylamino)ethoxy]anilino]-4h-pyrimido[4,5-d]pyrimidin-2-yl]-3-ethylurea Chemical compound N=1C=C2CN(C=3C(=C(OC)C=C(OC)C=3)Cl)C(NC(=O)NCC)=NC2=NC=1NC1=CC=C(OCCN(CC)CC)C=C1 JMNNHVDOWHBZGS-UHFFFAOYSA-N 0.000 claims description 2
- JMZBFDDWDQKWEU-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-7-[4-(4-methylpiperazin-1-yl)anilino]pyrido[4,3-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(CCCN(C)C)C2=CC=1NC(C=C1)=CC=C1N1CCN(C)CC1 JMZBFDDWDQKWEU-UHFFFAOYSA-N 0.000 claims description 2
- FAKVFHGYAUSYSU-UHFFFAOYSA-N 1-[7-(4-piperazin-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-yl]-3-propan-2-ylurea Chemical compound N=1C2=NC(NC(=O)NC(C)C)=NC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 FAKVFHGYAUSYSU-UHFFFAOYSA-N 0.000 claims description 2
- SEGPMNJSRKJLRF-UHFFFAOYSA-N 1-cyclopentyl-7-(4-fluoro-3-methylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=C(F)C(C)=CC(NC=2N=C3N(C4CCCC4)C(=O)N=CC3=CN=2)=C1 SEGPMNJSRKJLRF-UHFFFAOYSA-N 0.000 claims description 2
- LYPJMMVRHFYBED-UHFFFAOYSA-N 1-cyclopentyl-7-(4-methylsulfonylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=C(C=NC(=O)N2C3CCCC3)C2=N1 LYPJMMVRHFYBED-UHFFFAOYSA-N 0.000 claims description 2
- CMPAWLHWVNKEHO-UHFFFAOYSA-N 1-cyclopentyl-7-(pyridin-4-ylamino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3CCCC3)C(=O)N=CC2=CN=C1NC1=CC=NC=C1 CMPAWLHWVNKEHO-UHFFFAOYSA-N 0.000 claims description 2
- MAFLMDDLVBFCJM-UHFFFAOYSA-N 1-cyclopentyl-7-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3CCCC3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 MAFLMDDLVBFCJM-UHFFFAOYSA-N 0.000 claims description 2
- CYLYLWLMVRIMFM-UHFFFAOYSA-N 1-hexa-2,4-dienyl-7-[4-(4-methylpiperazin-1-yl)anilino]-3,4-dihydropyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC=CC=CC)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCN(C)CC1 CYLYLWLMVRIMFM-UHFFFAOYSA-N 0.000 claims description 2
- MXEAYMDSLOTGOA-UHFFFAOYSA-N 1-hexa-2,4-dienyl-7-[4-(4-methylpiperazin-1-yl)anilino]pyrido[4,3-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(CC=CC=CC)C2=CC=1NC(C=C1)=CC=C1N1CCN(C)CC1 MXEAYMDSLOTGOA-UHFFFAOYSA-N 0.000 claims description 2
- WGFUGBMZQCPOMB-UHFFFAOYSA-N 1-methyl-7-(4-pyrazol-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C)C2=NC=1NC(C=C1)=CC=C1N1C=CC=N1 WGFUGBMZQCPOMB-UHFFFAOYSA-N 0.000 claims description 2
- FAIRRWVQRAQPBG-UHFFFAOYSA-N 1-tert-butyl-3-[3-(2-chloro-3,5-dimethoxyphenyl)-7-[4-[2-(diethylamino)ethoxy]anilino]-4h-pyrimido[4,5-d]pyrimidin-2-yl]urea Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(CN(C(NC(=O)NC(C)(C)C)=N2)C=3C(=C(OC)C=C(OC)C=3)Cl)C2=N1 FAIRRWVQRAQPBG-UHFFFAOYSA-N 0.000 claims description 2
- VPNHAJYZVQXPDL-UHFFFAOYSA-N 2-[4-(2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl)anilino]-8-cyclopentyl-8h-pyrido[4,3-d]pyrimidin-7-one Chemical compound O=C1N=CC2=CN=C(NC=3C=CC(=CC=3)N3CC4CNCC4C3)N=C2C1C1CCCC1 VPNHAJYZVQXPDL-UHFFFAOYSA-N 0.000 claims description 2
- UFSSFDMEEMIJIW-UHFFFAOYSA-N 2-[4-(3-aminopyrrolidin-1-yl)anilino]-8-propan-2-yl-8h-pyrido[4,3-d]pyrimidin-7-one Chemical compound N1=C2C(C(C)C)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N1CCC(N)C1 UFSSFDMEEMIJIW-UHFFFAOYSA-N 0.000 claims description 2
- KQVTUIKOGACPKS-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-8-cyclopentyl-8h-pyrido[4,3-d]pyrimidin-7-one Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)C2C3CCCC3)C2=N1 KQVTUIKOGACPKS-UHFFFAOYSA-N 0.000 claims description 2
- SLSXXMZCLRYNCE-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)anilino]-8-propan-2-ylpyrimido[4,5-d]pyrimidine-5,7-dione Chemical compound N=1C=C2C(=O)NC(=O)N(C(C)C)C2=NC=1NC(C=C1)=CC=C1N1CCN(C)CC1 SLSXXMZCLRYNCE-UHFFFAOYSA-N 0.000 claims description 2
- CCECTNAHAIMUMV-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-6-(3,5-dimethoxyphenyl)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(CN(C(=O)N2)C=3C=C(OC)C=C(OC)C=3)C2=N1 CCECTNAHAIMUMV-UHFFFAOYSA-N 0.000 claims description 2
- DKTBRRPWLIMTOU-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-propan-2-ylpyrimido[4,5-d]pyrimidine-5,7-dione Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C2C(=O)NC(=O)N(C(C)C)C2=N1 DKTBRRPWLIMTOU-UHFFFAOYSA-N 0.000 claims description 2
- NNXCBTRERGAZEA-UHFFFAOYSA-N 3-(2,6-dichloro-3-hydroxyphenyl)-7-[3-(hydroxymethyl)anilino]-1-methyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C)C(=O)N(C=3C(=C(O)C=CC=3Cl)Cl)CC2=CN=C1NC1=CC=CC(CO)=C1 NNXCBTRERGAZEA-UHFFFAOYSA-N 0.000 claims description 2
- ZMJAWSDJCUMJJN-UHFFFAOYSA-N 3-(2,6-dichloro-3-hydroxyphenyl)-7-[4-[2-(ethylamino)ethoxy]anilino]-1-methyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OCCNCC)=CC=C1NC1=NC=C(CN(C(=O)N2C)C=3C(=C(O)C=CC=3Cl)Cl)C2=N1 ZMJAWSDJCUMJJN-UHFFFAOYSA-N 0.000 claims description 2
- DDHHWHJBJCYDFY-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(pyridin-4-ylamino)-4h-pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NC1=CC=NC=C1 DDHHWHJBJCYDFY-UHFFFAOYSA-N 0.000 claims description 2
- BKHNPXOUNMTMCY-UHFFFAOYSA-N 3-[[3-(2,6-dichlorophenyl)-1-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-7-yl]amino]benzoic acid Chemical compound N1=C2N(C)C(=O)N(C=3C(=CC=CC=3Cl)Cl)CC2=CN=C1NC1=CC=CC(C(O)=O)=C1 BKHNPXOUNMTMCY-UHFFFAOYSA-N 0.000 claims description 2
- ZGVAHFAZEXHQBU-UHFFFAOYSA-N 3-methyl-n-[2-[4-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)anilino]-5,8-dihydropyrimido[4,5-d]pyrimidin-7-yl]butanamide Chemical compound N=1C=C2CNC(NC(=O)CC(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1CC2CN(C)CC2C1 ZGVAHFAZEXHQBU-UHFFFAOYSA-N 0.000 claims description 2
- YXBONTSNICHWOF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-(4-morpholin-4-ylanilino)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound ClC1=CC=CC(Cl)=C1N1C(=O)NC2=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C2C1 YXBONTSNICHWOF-UHFFFAOYSA-N 0.000 claims description 2
- FURMGBUEINENHF-UHFFFAOYSA-N 6-(2-chloro-3,5-dimethoxyphenyl)-2-(pyridin-4-ylamino)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound COC1=CC(OC)=C(Cl)C(N2C(NC3=NC(NC=4C=CN=CC=4)=NC=C3C2)=O)=C1 FURMGBUEINENHF-UHFFFAOYSA-N 0.000 claims description 2
- DOOJZDPZTQALFP-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)-2-(pyridin-4-ylamino)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound COC1=CC(OC)=CC(N2C(NC3=NC(NC=4C=CN=CC=4)=NC=C3C2)=O)=C1 DOOJZDPZTQALFP-UHFFFAOYSA-N 0.000 claims description 2
- MHXYCBHAWRYEJN-UHFFFAOYSA-N 7-[4-(3-aminopyrrolidin-1-yl)anilino]-1-cyclopentylpyrimido[4,5-d]pyrimidin-2-one Chemical compound C1C(N)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C3CCCC3)C2=N1 MHXYCBHAWRYEJN-UHFFFAOYSA-N 0.000 claims description 2
- WEGXBFXGEMSMBV-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(2-phenylmethoxyethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1CNC(=O)N2CCOCC1=CC=CC=C1 WEGXBFXGEMSMBV-UHFFFAOYSA-N 0.000 claims description 2
- KNVFKFJFTHVEEB-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(2-phenylmethoxyethyl)pyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2CCOCC1=CC=CC=C1 KNVFKFJFTHVEEB-UHFFFAOYSA-N 0.000 claims description 2
- KBSKETZKORDXGH-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(pyridin-4-ylmethyl)pyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2CC1=CC=NC=C1 KBSKETZKORDXGH-UHFFFAOYSA-N 0.000 claims description 2
- UGBABPYASJQMRN-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(thiophen-2-ylmethyl)pyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2CC1=CC=CS1 UGBABPYASJQMRN-UHFFFAOYSA-N 0.000 claims description 2
- GLTDXDSGLSKBFN-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-prop-2-ynylpyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2CC#C GLTDXDSGLSKBFN-UHFFFAOYSA-N 0.000 claims description 2
- ZRZBLKRBDZWZSZ-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-thiophen-2-yl-3,4-dihydropyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1CNC(=O)N2C1=CC=CS1 ZRZBLKRBDZWZSZ-UHFFFAOYSA-N 0.000 claims description 2
- UHJBYYIBBRBGGM-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-thiophen-2-ylpyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2C1=CC=CS1 UHJBYYIBBRBGGM-UHFFFAOYSA-N 0.000 claims description 2
- QKLOVEMJMBZZGM-UHFFFAOYSA-N 7-[4-(diethylamino)butylamino]-3-(3,5-dimethoxyphenyl)-1-ethylpyrimido[4,5-d]pyrimidine-2,4-dione Chemical compound N=1C(NCCCCN(CC)CC)=NC=C(C2=O)C=1N(CC)C(=O)N2C1=CC(OC)=CC(OC)=C1 QKLOVEMJMBZZGM-UHFFFAOYSA-N 0.000 claims description 2
- OAFBQFMUZBKQGR-UHFFFAOYSA-N 7-[4-[2-(diethylamino)ethoxy]anilino]-3-(3,5-dimethoxyphenyl)-1-ethylpyrimido[4,5-d]pyrimidine-2,4-dione Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C2C(=O)N(C=3C=C(OC)C=C(OC)C=3)C(=O)N(CC)C2=N1 OAFBQFMUZBKQGR-UHFFFAOYSA-N 0.000 claims description 2
- QWSVKVIPPZIRTF-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-ethyl-4h-pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3Cl)Cl)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 QWSVKVIPPZIRTF-UHFFFAOYSA-N 0.000 claims description 2
- DSRALOQZPSABQW-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3Cl)Cl)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 DSRALOQZPSABQW-UHFFFAOYSA-N 0.000 claims description 2
- ZPHLSRPTAYKNSC-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-4h-pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3)Cl)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 ZPHLSRPTAYKNSC-UHFFFAOYSA-N 0.000 claims description 2
- MZNBPCTXGRSFID-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3)Cl)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 MZNBPCTXGRSFID-UHFFFAOYSA-N 0.000 claims description 2
- IGZXOAHEJUNVIM-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-4h-pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3)C)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 IGZXOAHEJUNVIM-UHFFFAOYSA-N 0.000 claims description 2
- OBULHFMDPLXVGG-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3)C)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 OBULHFMDPLXVGG-UHFFFAOYSA-N 0.000 claims description 2
- VWJYAHJZYPEERG-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(3,5-dimethoxyphenyl)-1-ethyl-4h-pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 VWJYAHJZYPEERG-UHFFFAOYSA-N 0.000 claims description 2
- XIRYXRPWCKNZKY-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(3,5-dimethoxyphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 XIRYXRPWCKNZKY-UHFFFAOYSA-N 0.000 claims description 2
- GQVGRZBPLJVVLQ-UHFFFAOYSA-N 8-(3-bicyclo[2.2.1]heptanyl)-2-(4-pyrazol-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3C4CCC(C4)C3)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1C=CC=N1 GQVGRZBPLJVVLQ-UHFFFAOYSA-N 0.000 claims description 2
- OTVNQBQXSHFVJW-UHFFFAOYSA-N 8-cyclopentyl-2-(4-fluoro-3-methylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1=C(F)C(C)=CC(NC=2N=C3N(C4CCCC4)C(=O)NCC3=CN=2)=C1 OTVNQBQXSHFVJW-UHFFFAOYSA-N 0.000 claims description 2
- ZIQXFQRBAGDAOJ-UHFFFAOYSA-N 8-cyclopentyl-2-(pyridin-4-ylamino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)NCC2=CN=C1NC1=CC=NC=C1 ZIQXFQRBAGDAOJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000043276 Oncogene Human genes 0.000 claims description 2
- 108700020796 Oncogene Proteins 0.000 claims description 2
- JTQWZEUEOCWMBZ-UHFFFAOYSA-N n-[7-[4-(3-aminopyrrolidin-1-yl)anilino]pyrimido[4,5-d]pyrimidin-2-yl]-3-methylbutanamide Chemical compound N=1C2=NC(NC(=O)CC(C)C)=NC=C2C=NC=1NC(C=C1)=CC=C1N1CCC(N)C1 JTQWZEUEOCWMBZ-UHFFFAOYSA-N 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 11
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 2
- REAXZCOCRIIZGW-UHFFFAOYSA-N 1-(3,5-dimethylheptyl)-7-[4-(4-methylpiperazin-1-yl)anilino]pyrido[4,3-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(CCC(C)CC(C)CC)C2=CC=1NC(C=C1)=CC=C1N1CCN(C)CC1 REAXZCOCRIIZGW-UHFFFAOYSA-N 0.000 claims 1
- VRKQHBMOSLPUBQ-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)-7-[4-(4-hydroxypiperidin-1-yl)anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1CC(O)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C3C4CCC(C4)C3)C2=N1 VRKQHBMOSLPUBQ-UHFFFAOYSA-N 0.000 claims 1
- IYXLABJEKVQWPX-UHFFFAOYSA-N 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(pyridin-4-ylamino)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound COC1=CC(OC)=C(Cl)C(N2C(NC3=NC(NC=4C=CN=CC=4)=NC=C3C2)=O)=C1Cl IYXLABJEKVQWPX-UHFFFAOYSA-N 0.000 claims 1
- BQJYNXDTDIXEHH-UHFFFAOYSA-N 7-[4-(4-hydroxypiperidin-1-yl)anilino]-1-propan-2-ylpyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C(C)C)C2=NC=1NC(C=C1)=CC=C1N1CCC(O)CC1 BQJYNXDTDIXEHH-UHFFFAOYSA-N 0.000 claims 1
- AVKZXEJUDBZKQD-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(pyridin-4-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1CNC(=O)N2CC1=CC=NC=C1 AVKZXEJUDBZKQD-UHFFFAOYSA-N 0.000 claims 1
- ZMORBAXKSQLQIT-UHFFFAOYSA-N 8-cyclopentyl-2-(4-methylsulfonylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 ZMORBAXKSQLQIT-UHFFFAOYSA-N 0.000 claims 1
- IHZPXGUDCVDZGJ-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1C2CN(C)CC2CN1C(C=C1)=CC=C1NC(N=C12)=NC=C1CNC(=O)N2C1CCCC1 IHZPXGUDCVDZGJ-UHFFFAOYSA-N 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000000276 sedentary effect Effects 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 302
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 196
- 239000000047 product Substances 0.000 description 117
- 235000019439 ethyl acetate Nutrition 0.000 description 105
- 239000000243 solution Substances 0.000 description 105
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 82
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 82
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 77
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- 238000004458 analytical method Methods 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 69
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 65
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- 239000007787 solid Substances 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 239000011541 reaction mixture Substances 0.000 description 56
- 239000000203 mixture Substances 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 46
- 238000002844 melting Methods 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 230000008018 melting Effects 0.000 description 44
- 239000000741 silica gel Substances 0.000 description 44
- 229910002027 silica gel Inorganic materials 0.000 description 44
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 41
- 238000002360 preparation method Methods 0.000 description 40
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 235000019341 magnesium sulphate Nutrition 0.000 description 30
- 239000000725 suspension Substances 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000000354 decomposition reaction Methods 0.000 description 24
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 19
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 13
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 12
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000012266 salt solution Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 108091007914 CDKs Proteins 0.000 description 9
- 102000001332 SRC Human genes 0.000 description 9
- 108060006706 SRC Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- DUEPCQAJHSIXBU-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-methylsulfinyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1C2=CN=C(S(C)=O)N=C2N(CC)C(=O)N1C1=CC(OC)=CC(OC)=C1 DUEPCQAJHSIXBU-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000012280 lithium aluminium hydride Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- LFNHDFNPTDIBJL-UHFFFAOYSA-N 2-methylsulfinyl-8-propan-2-yl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C(S(C)=O)N=C2N(C(C)C)C(=O)NCC2=C1 LFNHDFNPTDIBJL-UHFFFAOYSA-N 0.000 description 7
- LTZFBTWHIPRKKQ-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)-2-methylsulfinyl-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound COC1=CC(OC)=CC(N2C(NC3=NC(=NC=C3C2)S(C)=O)=O)=C1 LTZFBTWHIPRKKQ-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- MKHGVMIXRPGHOO-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-phenyloxaziridine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1OC1C1=CC=CC=C1 MKHGVMIXRPGHOO-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- MOZNZNKHRXRLLF-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1 MOZNZNKHRXRLLF-UHFFFAOYSA-N 0.000 description 5
- IGIRTCCCRNZFSQ-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(Cl)=N1 IGIRTCCCRNZFSQ-UHFFFAOYSA-N 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 5
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- 102000014400 SH2 domains Human genes 0.000 description 5
- 108050003452 SH2 domains Proteins 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 150000003462 sulfoxides Chemical group 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- WUEPMEXUMQVEGN-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-n-[2-[2-[(2,2,2-trifluoroacetyl)amino]ethylamino]ethyl]acetamide Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C(=O)NCCNCCNC(=O)C(F)(F)F WUEPMEXUMQVEGN-UHFFFAOYSA-N 0.000 description 4
- TVMDANWYLLBFIA-UHFFFAOYSA-N 8-methyl-2-methylsulfinyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C(S(C)=O)N=C2N(C)C(=O)NCC2=C1 TVMDANWYLLBFIA-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 150000001448 anilines Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical class CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 4
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 3
- BJXPIIDUCADEKU-UHFFFAOYSA-N 1-(4-aminophenyl)piperidin-4-ol Chemical compound C1=CC(N)=CC=C1N1CCC(O)CC1 BJXPIIDUCADEKU-UHFFFAOYSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- JMQVKBJBHQXSAV-UHFFFAOYSA-N 2-methylsulfanyl-4-(propan-2-ylamino)pyrimidine-5-carbonyl chloride Chemical compound CSC1=NC=C(C(Cl)=O)C(NC(C)C)=N1 JMQVKBJBHQXSAV-UHFFFAOYSA-N 0.000 description 3
- BEOJZKXSSGNRAI-UHFFFAOYSA-N 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-7-methylsulfinyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1C2=CN=C(S(C)=O)N=C2N(CC)C(=O)N1C1=CC(OC)=CC(OC)=C1Cl BEOJZKXSSGNRAI-UHFFFAOYSA-N 0.000 description 3
- SBIOXJSYZDQFII-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)-2-methylsulfanyl-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound COC1=CC(OC)=CC(N2C(NC3=NC(SC)=NC=C3C2)=O)=C1 SBIOXJSYZDQFII-UHFFFAOYSA-N 0.000 description 3
- STSHETKCOZLESG-UHFFFAOYSA-N 8-cyclopentyl-2-methylsulfinyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C12=NC(S(=O)C)=NC=C2CNC(=O)N1C1CCCC1 STSHETKCOZLESG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- UKNRWOLNLTUUGU-UHFFFAOYSA-N ethyl 2-methylsulfanyl-4-(propan-2-ylamino)pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1NC(C)C UKNRWOLNLTUUGU-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 150000003141 primary amines Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
- 229940048086 sodium pyrophosphate Drugs 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- UGSAFYXJUYQMMB-UHFFFAOYSA-N (2-chloro-3,5-dimethoxyphenyl)carbamic acid Chemical compound COC1=CC(NC(O)=O)=C(Cl)C(OC)=C1 UGSAFYXJUYQMMB-UHFFFAOYSA-N 0.000 description 2
- OOJYJQIMJKZUSJ-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)-7-[4-(4-methylpiperazin-1-yl)anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C3C4CCC(C4)C3)C2=N1 OOJYJQIMJKZUSJ-UHFFFAOYSA-N 0.000 description 2
- PFDUBQQHEHJNQX-UHFFFAOYSA-N 1-(4-aminophenyl)-n,n-dimethylpiperidin-4-amine Chemical compound C1CC(N(C)C)CCN1C1=CC=C(N)C=C1 PFDUBQQHEHJNQX-UHFFFAOYSA-N 0.000 description 2
- VFMDZLAXEZDDIB-UHFFFAOYSA-N 1-cyclopentyl-7-[4-[2-(diethylamino)ethoxy]-3-methylanilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=C(C)C(OCCN(CC)CC)=CC=C1NC1=NC=C(C=NC(=O)N2C3CCCC3)C2=N1 VFMDZLAXEZDDIB-UHFFFAOYSA-N 0.000 description 2
- KAHIEOWPOWHUDI-UHFFFAOYSA-N 1-methyl-7-[4-(4-methylpiperazin-1-yl)anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C)C2=N1 KAHIEOWPOWHUDI-UHFFFAOYSA-N 0.000 description 2
- KQYRLYXVCBSQJQ-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)anilino]-8-methyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCC(O)CC1 KQYRLYXVCBSQJQ-UHFFFAOYSA-N 0.000 description 2
- BPQWUDKYRDQMHG-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)anilino]-8-propan-2-yl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C(C)C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCC(O)CC1 BPQWUDKYRDQMHG-UHFFFAOYSA-N 0.000 description 2
- QIEARILFCPQQSI-UHFFFAOYSA-N 2-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-8-methyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CC(N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C)C2=N1 QIEARILFCPQQSI-UHFFFAOYSA-N 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
- QAQJMSZWWPFNJB-UHFFFAOYSA-N 2-chloro-3,5-dimethoxyaniline Chemical compound COC1=CC(N)=C(Cl)C(OC)=C1 QAQJMSZWWPFNJB-UHFFFAOYSA-N 0.000 description 2
- UMQJAFDUZIGZMO-UHFFFAOYSA-N 2-chloro-3,5-dimethoxybenzoic acid Chemical compound COC1=CC(OC)=C(Cl)C(C(O)=O)=C1 UMQJAFDUZIGZMO-UHFFFAOYSA-N 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 2
- GEYBMRSYETXWKQ-UHFFFAOYSA-N 2-methylsulfanyl-4-(propan-2-ylamino)pyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(NC(C)C)=N1 GEYBMRSYETXWKQ-UHFFFAOYSA-N 0.000 description 2
- IPIYOTSHMSSGLY-UHFFFAOYSA-N 2-methylsulfanyl-4-(propan-2-ylamino)pyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC(C)C)=N1 IPIYOTSHMSSGLY-UHFFFAOYSA-N 0.000 description 2
- XTLKENCFQIAAJK-UHFFFAOYSA-N 2-methylsulfanyl-6-oxo-1h-pyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(=O)N1 XTLKENCFQIAAJK-UHFFFAOYSA-N 0.000 description 2
- WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-Dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 2
- JTYNTVUTBFVANC-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-methylsulfanyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1C2=CN=C(SC)N=C2N(CC)C(=O)N1C1=CC(OC)=CC(OC)=C1 JTYNTVUTBFVANC-UHFFFAOYSA-N 0.000 description 2
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 2
- NXKRSMDVDRFSBV-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)butan-1-amine Chemical compound CN1CCN(CCCCN)CC1 NXKRSMDVDRFSBV-UHFFFAOYSA-N 0.000 description 2
- HJEICQFETFKTLG-UHFFFAOYSA-N 4-(cyclopentylamino)-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(NC2CCCC2)=N1 HJEICQFETFKTLG-UHFFFAOYSA-N 0.000 description 2
- GHSAKUXIRGLXHH-UHFFFAOYSA-N 4-(ethylamino)-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CCNC1=NC(SC)=NC=C1C=O GHSAKUXIRGLXHH-UHFFFAOYSA-N 0.000 description 2
- JXLBJMVSMOLNHO-UHFFFAOYSA-N 4-(methylamino)-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CNC1=NC(SC)=NC=C1C#N JXLBJMVSMOLNHO-UHFFFAOYSA-N 0.000 description 2
- LFJGGGIWERIGNX-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]aniline Chemical compound CCN(CC)CCOC1=CC=C(N)C=C1 LFJGGGIWERIGNX-UHFFFAOYSA-N 0.000 description 2
- XMYJIRKAMFCJSV-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)pentan-1-amine Chemical compound CN1CCN(CCCCCN)CC1 XMYJIRKAMFCJSV-UHFFFAOYSA-N 0.000 description 2
- OHQZZAHOSGKRJC-UHFFFAOYSA-N 5-(aminomethyl)-2-methylsulfanyl-n-propan-2-ylpyrimidin-4-amine Chemical compound CSC1=NC=C(CN)C(NC(C)C)=N1 OHQZZAHOSGKRJC-UHFFFAOYSA-N 0.000 description 2
- VYGFIZHPKQIHMZ-UHFFFAOYSA-N 5-(aminomethyl)-n-cyclopentyl-2-methylsulfanylpyrimidin-4-amine Chemical compound CSC1=NC=C(CN)C(NC2CCCC2)=N1 VYGFIZHPKQIHMZ-UHFFFAOYSA-N 0.000 description 2
- WTILQKOVXMLHPA-UHFFFAOYSA-N 5-(aminomethyl)-n-methyl-2-methylsulfanylpyrimidin-4-amine Chemical compound CNC1=NC(SC)=NC=C1CN WTILQKOVXMLHPA-UHFFFAOYSA-N 0.000 description 2
- XIDLIYWLKWKLNF-UHFFFAOYSA-N 5-[(2-chloro-3,5-dimethoxyanilino)methyl]-n-ethyl-2-methylsulfanylpyrimidin-4-amine Chemical compound CCNC1=NC(SC)=NC=C1CNC1=CC(OC)=CC(OC)=C1Cl XIDLIYWLKWKLNF-UHFFFAOYSA-N 0.000 description 2
- NDTOYDDFLQNXNH-UHFFFAOYSA-N 5-[(3,5-dimethoxyanilino)methyl]-2-methylsulfanylpyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(NCC=2C(=NC(SC)=NC=2)N)=C1 NDTOYDDFLQNXNH-UHFFFAOYSA-N 0.000 description 2
- IDENZAFGZDVXKB-UHFFFAOYSA-N 7-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-1-methylpyrimido[4,5-d]pyrimidin-2-one Chemical compound C1CC(N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C)C2=N1 IDENZAFGZDVXKB-UHFFFAOYSA-N 0.000 description 2
- BLXKYKWCQVMZNY-UHFFFAOYSA-N 7-imidazol-1-yl-3-[(4-methoxyphenyl)methyl]-1-propan-2-ylpyrimido[4,5-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C2=CN=C(N3C=NC=C3)N=C2N(C(C)C)C1=O BLXKYKWCQVMZNY-UHFFFAOYSA-N 0.000 description 2
- DHJCMDIDXIUWQC-UHFFFAOYSA-N 8,8,8-trifluorooct-1-ene Chemical compound FC(F)(F)CCCCCC=C DHJCMDIDXIUWQC-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 241000514744 Cyclina Species 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 101150093908 PDGFRB gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000003713 acetylimino group Chemical group [H]C([H])([H])C(=O)N=[*] 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000000515 cyanogenic effect Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- JILXUIANNUALRZ-UHFFFAOYSA-N n',n'-diethylbutane-1,4-diamine Chemical compound CCN(CC)CCCCN JILXUIANNUALRZ-UHFFFAOYSA-N 0.000 description 2
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 description 2
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- QGDYVSSVBYMOJN-UHFFFAOYSA-N pyrimido[4,5-d]pyrimidine Chemical class C1=NC=NC2=NC=NC=C21 QGDYVSSVBYMOJN-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- JEPPYVOSGKWVSJ-RRKCRQDMSA-N (1s,3r,4r)-bicyclo[2.2.1]heptan-3-amine Chemical compound C1C[C@H]2[C@H](N)C[C@@H]1C2 JEPPYVOSGKWVSJ-RRKCRQDMSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- GFPPPMAWVWTROZ-UHFFFAOYSA-N 1-(4-aminophenyl)piperidin-3-ol Chemical compound C1=CC(N)=CC=C1N1CC(O)CCC1 GFPPPMAWVWTROZ-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- ZJKUELGTFKGMLG-UHFFFAOYSA-N 1-cyclopentyl-7-(4-methoxyanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(C=NC(=O)N2C3CCCC3)C2=N1 ZJKUELGTFKGMLG-UHFFFAOYSA-N 0.000 description 1
- HSHLNEJOCHYTQO-UHFFFAOYSA-N 1-cyclopentyl-7-(4-piperazin-1-ylanilino)pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(C3CCCC3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 HSHLNEJOCHYTQO-UHFFFAOYSA-N 0.000 description 1
- SIIGOVZBTPGWRM-UHFFFAOYSA-N 1-cyclopentyl-7-(4-piperazin-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3CCCC3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 SIIGOVZBTPGWRM-UHFFFAOYSA-N 0.000 description 1
- GVOKCKNBJFWYMI-UHFFFAOYSA-N 1-cyclopentyl-7-(4-piperidin-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3CCCC3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N1CCCCC1 GVOKCKNBJFWYMI-UHFFFAOYSA-N 0.000 description 1
- LCUDSUMNCZALSG-UHFFFAOYSA-N 1-cyclopentyl-7-(4-pyrazol-1-ylanilino)pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(C3CCCC3)C(=O)N=CC2=CN=C1NC(C=C1)=CC=C1N1C=CC=N1 LCUDSUMNCZALSG-UHFFFAOYSA-N 0.000 description 1
- CETJKWMLOZBBRP-UHFFFAOYSA-N 1-cyclopentyl-7-[4-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1C2CN(C)CC2CN1C(C=C1)=CC=C1NC(N=C12)=NC=C1C=NC(=O)N2C1CCCC1 CETJKWMLOZBBRP-UHFFFAOYSA-N 0.000 description 1
- HFXXMKXIPRZNCR-UHFFFAOYSA-N 1-cyclopentyl-7-[4-(4-hydroxypiperidin-1-yl)anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1CC(O)CCN1C(C=C1)=CC=C1NC1=NC=C(C=NC(=O)N2C3CCCC3)C2=N1 HFXXMKXIPRZNCR-UHFFFAOYSA-N 0.000 description 1
- IMKFEYLQHSBAQD-UHFFFAOYSA-N 1-methyl-7-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]pyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C)C2=NC=1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 IMKFEYLQHSBAQD-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- NCBMKQMKSYQZJC-UHFFFAOYSA-N 1-propan-2-yl-3-[7-(pyridin-4-ylamino)pyrimido[4,5-d]pyrimidin-2-yl]urea Chemical compound N=1C2=NC(NC(=O)NC(C)C)=NC=C2C=NC=1NC1=CC=NC=C1 NCBMKQMKSYQZJC-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QZFBFZJTMQUWEX-UHFFFAOYSA-N 2-[3-(diethylamino)propylamino]-6-(3,5-dimethoxyphenyl)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound O=C1NC2=NC(NCCCN(CC)CC)=NC=C2CN1C1=CC(OC)=CC(OC)=C1 QZFBFZJTMQUWEX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SJMBXVBBKAGPHL-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)anilino]-8-propan-2-yl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C(C)C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCN(C)CC1 SJMBXVBBKAGPHL-UHFFFAOYSA-N 0.000 description 1
- RDVVIEPRRSJLHP-UHFFFAOYSA-N 2-[4-(diethylamino)butylamino]-6-(3,5-dimethoxyphenyl)-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound O=C1NC2=NC(NCCCCN(CC)CC)=NC=C2CN1C1=CC(OC)=CC(OC)=C1 RDVVIEPRRSJLHP-UHFFFAOYSA-N 0.000 description 1
- XQFJWOGRDORMKR-UHFFFAOYSA-N 2-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]-8-propan-2-yl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C(C)C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 XQFJWOGRDORMKR-UHFFFAOYSA-N 0.000 description 1
- JJRJEVUSKRUNDL-UHFFFAOYSA-N 2-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-8-propan-2-yl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C(C)C)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCC(N(C)C)CC1 JJRJEVUSKRUNDL-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- GKYPAONSKSSROB-UHFFFAOYSA-N 2-methylsulfanyl-4,5-dihydropyrimidine Chemical compound CSC1=NCCC=N1 GKYPAONSKSSROB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OWIPTLWIAXXGHB-UHFFFAOYSA-N 2-pyridin-2-ylpropanedioic acid Chemical compound OC(=O)C(C(O)=O)C1=CC=CC=N1 OWIPTLWIAXXGHB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SDEFUULZTYAIPF-UHFFFAOYSA-N 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[4-[2-(diethylamino)ethoxy]anilino]-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(CN(C(=O)N2CC)C=3C(=C(OC)C=C(OC)C=3Cl)Cl)C2=N1 SDEFUULZTYAIPF-UHFFFAOYSA-N 0.000 description 1
- HPSGUKXETOSKQL-UHFFFAOYSA-N 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-7-(pyridin-4-ylamino)-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3)Cl)CC2=CN=C1NC1=CC=NC=C1 HPSGUKXETOSKQL-UHFFFAOYSA-N 0.000 description 1
- BIWXKMYKMAPEIV-UHFFFAOYSA-N 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-7-methylsulfanyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1C2=CN=C(SC)N=C2N(CC)C(=O)N1C1=CC(OC)=CC(OC)=C1Cl BIWXKMYKMAPEIV-UHFFFAOYSA-N 0.000 description 1
- FAEKZTNYXIGRKR-UHFFFAOYSA-N 3-(2-chloro-3,5-dimethoxyphenyl)-7-[4-(diethylamino)butylamino]-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound O=C1N(CC)C2=NC(NCCCCN(CC)CC)=NC=C2CN1C1=CC(OC)=CC(OC)=C1Cl FAEKZTNYXIGRKR-UHFFFAOYSA-N 0.000 description 1
- UFIKWIICZUYKTH-UHFFFAOYSA-N 3-(2-chloro-3,5-dimethoxyphenyl)-7-[4-[2-(diethylamino)ethoxy]anilino]-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(CN(C(=O)N2CC)C=3C(=C(OC)C=C(OC)C=3)Cl)C2=N1 UFIKWIICZUYKTH-UHFFFAOYSA-N 0.000 description 1
- OHVWWJZFAXWHHP-UHFFFAOYSA-N 3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-7-(pyridin-4-ylamino)-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3)C)CC2=CN=C1NC1=CC=NC=C1 OHVWWJZFAXWHHP-UHFFFAOYSA-N 0.000 description 1
- YHLJODALDPVKPX-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(pyridin-4-ylamino)-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NC1=CC=NC=C1 YHLJODALDPVKPX-UHFFFAOYSA-N 0.000 description 1
- SASAJJQXTORYMM-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(pyridin-4-ylamino)pyrimido[4,5-d]pyrimidine-2,4-dione Chemical compound N=1C=C2C(=O)N(C=3C=C(OC)C=C(OC)C=3)C(=O)N(CC)C2=NC=1NC1=CC=NC=C1 SASAJJQXTORYMM-UHFFFAOYSA-N 0.000 description 1
- RWINHFXDGDLNBY-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-[3-(4-methylpiperazin-1-yl)propylamino]-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NCCCN1CCN(C)CC1 RWINHFXDGDLNBY-UHFFFAOYSA-N 0.000 description 1
- FKDKQKKQSCAYFI-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-[4-(4-methylpiperazin-1-yl)butylamino]-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NCCCCN1CCN(C)CC1 FKDKQKKQSCAYFI-UHFFFAOYSA-N 0.000 description 1
- ZUCAKYBJNRNMNB-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-1-ethyl-7-[5-(4-methylpiperazin-1-yl)pentylamino]-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C=C(OC)C=C(OC)C=3)CC2=CN=C1NCCCCCN1CCN(C)CC1 ZUCAKYBJNRNMNB-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- RHMVAEDRHIPTGQ-UHFFFAOYSA-N 3-[1-(4-aminophenyl)piperidin-4-yl]propan-1-ol Chemical compound C1=CC(N)=CC=C1N1CCC(CCCO)CC1 RHMVAEDRHIPTGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- XVBTTZLOWSXZLV-UHFFFAOYSA-N 3-methyl-n-[7-(pyridin-4-ylamino)pyrimido[4,5-d]pyrimidin-2-yl]butanamide Chemical compound N=1C2=NC(NC(=O)CC(C)C)=NC=C2C=NC=1NC1=CC=NC=C1 XVBTTZLOWSXZLV-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VIRQUEIJJVFAQB-UHFFFAOYSA-N 4,5-dihydropyrimidin-2-amine Chemical compound NC1=NCCC=N1 VIRQUEIJJVFAQB-UHFFFAOYSA-N 0.000 description 1
- FPBFBURPCHKEKH-UHFFFAOYSA-N 4-(3,5-dimethylpiperazin-1-yl)aniline Chemical compound C1C(C)NC(C)CN1C1=CC=C(N)C=C1 FPBFBURPCHKEKH-UHFFFAOYSA-N 0.000 description 1
- CRDMYSDVVQBQEZ-UHFFFAOYSA-N 4-(3-bicyclo[2.2.1]heptanylamino)-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(NC2C3CCC(C3)C2)=N1 CRDMYSDVVQBQEZ-UHFFFAOYSA-N 0.000 description 1
- PNMMEFGEXFGFOQ-UHFFFAOYSA-N 4-(4-pyrazol-1-ylpiperidin-1-yl)aniline Chemical compound C1=CC(N)=CC=C1N1CCC(N2N=CC=C2)CC1 PNMMEFGEXFGFOQ-UHFFFAOYSA-N 0.000 description 1
- ZAEKMFPFNPVTMX-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]-3-methylaniline Chemical compound CCN(CC)CCOC1=CC=C(N)C=C1C ZAEKMFPFNPVTMX-UHFFFAOYSA-N 0.000 description 1
- CCCVQPGAXZNTIL-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]aniline Chemical compound CN(C)CCOC1=CC=C(N)C=C1 CCCVQPGAXZNTIL-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FGONQMFYFJRAIG-UHFFFAOYSA-N 4-amino-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(N)=N1 FGONQMFYFJRAIG-UHFFFAOYSA-N 0.000 description 1
- VYDHBDPZNLVELI-UHFFFAOYSA-N 4-amino-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(N)=N1 VYDHBDPZNLVELI-UHFFFAOYSA-N 0.000 description 1
- CXBIOJPHYXROIJ-UHFFFAOYSA-N 4-chloro-6-methylsulfanylpyridine-3-carbonitrile Chemical compound CSC1=CC(Cl)=C(C#N)C=N1 CXBIOJPHYXROIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- TVOSOIXYPHKEAR-UHFFFAOYSA-N 4-piperidin-1-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCCCC1 TVOSOIXYPHKEAR-UHFFFAOYSA-N 0.000 description 1
- CSFIQHZIFKIQNO-UHFFFAOYSA-N 4-pyrazol-1-ylaniline Chemical compound C1=CC(N)=CC=C1N1N=CC=C1 CSFIQHZIFKIQNO-UHFFFAOYSA-N 0.000 description 1
- NHLHWHRXMZZWGA-UHFFFAOYSA-N 4-pyrrol-1-ylaniline Chemical compound C1=CC(N)=CC=C1N1C=CC=C1 NHLHWHRXMZZWGA-UHFFFAOYSA-N 0.000 description 1
- YWAYJPPPWVEGAQ-UHFFFAOYSA-N 5-(aminomethyl)-2-methylsulfanylpyrimidin-4-amine Chemical class CSC1=NC=C(CN)C(N)=N1 YWAYJPPPWVEGAQ-UHFFFAOYSA-N 0.000 description 1
- KIZOMUNPKDSPGS-UHFFFAOYSA-N 5-(aminomethyl)-n-(3-bicyclo[2.2.1]heptanyl)-2-methylsulfanylpyrimidin-4-amine Chemical compound CSC1=NC=C(CN)C(NC2C3CCC(C3)C2)=N1 KIZOMUNPKDSPGS-UHFFFAOYSA-N 0.000 description 1
- TYYISYFEKSVPNH-UHFFFAOYSA-N 5-[(2-chloro-3,5-dimethoxyphenyl)iminomethyl]-n-ethyl-2-methylsulfanylpyrimidin-4-amine Chemical compound CCNC1=NC(SC)=NC=C1C=NC1=CC(OC)=CC(OC)=C1Cl TYYISYFEKSVPNH-UHFFFAOYSA-N 0.000 description 1
- FIUNXTTUCBEUFY-UHFFFAOYSA-N 5-[(3,5-dimethoxyanilino)methyl]-n-ethyl-2-methylsulfanylpyrimidin-4-amine Chemical compound CCNC1=NC(SC)=NC=C1CNC1=CC(OC)=CC(OC)=C1 FIUNXTTUCBEUFY-UHFFFAOYSA-N 0.000 description 1
- VHHRRUHHQOAWHG-UHFFFAOYSA-N 5-[(3,5-dimethoxyphenyl)iminomethyl]-2-methylsulfanylpyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(N=CC=2C(=NC(SC)=NC=2)N)=C1 VHHRRUHHQOAWHG-UHFFFAOYSA-N 0.000 description 1
- YPXQSGWOGQPLQO-UHFFFAOYSA-N 5-nitro-1,3-dihydrobenzimidazole-2-thione Chemical compound [O-][N+](=O)C1=CC=C2N=C(S)NC2=C1 YPXQSGWOGQPLQO-UHFFFAOYSA-N 0.000 description 1
- IMYMTYWGMCNGQR-UHFFFAOYSA-N 6-(2-chloro-3,5-dimethoxyphenyl)-2-[4-(diethylamino)butylamino]-5,8-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound O=C1NC2=NC(NCCCCN(CC)CC)=NC=C2CN1C1=CC(OC)=CC(OC)=C1Cl IMYMTYWGMCNGQR-UHFFFAOYSA-N 0.000 description 1
- FCCQSUPJLVRAMQ-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)-2-methylsulfinyl-5h-pyrimido[4,5-d]pyrimidin-7-amine Chemical compound COC1=CC(OC)=CC(N2C(=NC3=NC(=NC=C3C2)S(C)=O)N)=C1 FCCQSUPJLVRAMQ-UHFFFAOYSA-N 0.000 description 1
- MQRLLRUSNGXIQU-UHFFFAOYSA-N 7-[3-(diethylamino)propylamino]-3-(3,5-dimethoxyphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound O=C1N(CC)C2=NC(NCCCN(CC)CC)=NC=C2CN1C1=CC(OC)=CC(OC)=C1 MQRLLRUSNGXIQU-UHFFFAOYSA-N 0.000 description 1
- QQKWYYBDQWQGBW-UHFFFAOYSA-N 7-[4-(3-aminopyrrolidin-1-yl)anilino]-1-cyclopentylpyrido[4,3-d]pyrimidin-2-one Chemical compound C1C(N)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2C1CCCC1 QQKWYYBDQWQGBW-UHFFFAOYSA-N 0.000 description 1
- YUQQELDYRJEPGY-UHFFFAOYSA-N 7-[4-(4-hydroxypiperidin-1-yl)anilino]-1-methylpyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C)C2=NC=1NC(C=C1)=CC=C1N1CCC(O)CC1 YUQQELDYRJEPGY-UHFFFAOYSA-N 0.000 description 1
- PLUWBBUHYKHWAV-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(oxolan-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1CNC(=O)N2C1OCCC1 PLUWBBUHYKHWAV-UHFFFAOYSA-N 0.000 description 1
- PGFXNGPZADRFHR-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)anilino]-1-(oxolan-2-yl)pyrido[4,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1)=CC2=C1C=NC(=O)N2C1OCCC1 PGFXNGPZADRFHR-UHFFFAOYSA-N 0.000 description 1
- VXFJOZYHQKILGZ-UHFFFAOYSA-N 7-[4-[2-(diethylamino)ethoxy]anilino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(CN(C(=O)N2CC)C=3C(=C(OC)C=C(OC)C=3C)C)C2=N1 VXFJOZYHQKILGZ-UHFFFAOYSA-N 0.000 description 1
- AKCXEGOMBQDXOR-UHFFFAOYSA-N 7-[4-[2-(diethylamino)ethoxy]anilino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(CN(C(=O)N2CC)C=3C(=C(OC)C=C(OC)C=3)C)C2=N1 AKCXEGOMBQDXOR-UHFFFAOYSA-N 0.000 description 1
- BOAJHWBJTRTDGH-UHFFFAOYSA-N 7-[4-[2-(diethylamino)ethoxy]anilino]-3-[(4-methoxyphenyl)methyl]-1-propan-2-ylpyrimido[4,5-d]pyrimidine-2,4-dione Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C2C(=O)N(CC=3C=CC(OC)=CC=3)C(=O)N(C(C)C)C2=N1 BOAJHWBJTRTDGH-UHFFFAOYSA-N 0.000 description 1
- VQAIRYJUPWCKIE-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-4h-pyrido[4,3-d]pyrimidin-2-one Chemical compound C1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3C)C)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 VQAIRYJUPWCKIE-UHFFFAOYSA-N 0.000 description 1
- PZWHMNAOMJTZTR-UHFFFAOYSA-N 7-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound N1=C2N(CC)C(=O)N(C=3C(=C(OC)C=C(OC)C=3C)C)CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 PZWHMNAOMJTZTR-UHFFFAOYSA-N 0.000 description 1
- BPGHVIYMZOHLEA-UHFFFAOYSA-N 7-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]-1-propan-2-ylpyrimido[4,5-d]pyrimidin-2-one Chemical compound N=1C=C2C=NC(=O)N(C(C)C)C2=NC=1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 BPGHVIYMZOHLEA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BLIXAOCXGZEAKH-UHFFFAOYSA-N 8-(3-bicyclo[2.2.1]heptanyl)-2-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3C4CCC(C4)C3)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 BLIXAOCXGZEAKH-UHFFFAOYSA-N 0.000 description 1
- ZMCLWCDWCHYVMB-UHFFFAOYSA-N 8-(3-bicyclo[2.2.1]heptanyl)-2-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CC(N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3C4CCC(C4)C3)C2=N1 ZMCLWCDWCHYVMB-UHFFFAOYSA-N 0.000 description 1
- UFDHQPCDIQJMCV-UHFFFAOYSA-N 8-(3-bicyclo[2.2.1]heptanyl)-2-methylsulfinyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C12=NC(S(=O)C)=NC=C2CNC(=O)N1C1C(C2)CCC2C1 UFDHQPCDIQJMCV-UHFFFAOYSA-N 0.000 description 1
- ACOFVSGNBRTYJC-UHFFFAOYSA-N 8-cyclopentyl-2-(4-methoxyanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 ACOFVSGNBRTYJC-UHFFFAOYSA-N 0.000 description 1
- NFGRNPCSGFFZQM-UHFFFAOYSA-N 8-cyclopentyl-2-(4-piperazin-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 NFGRNPCSGFFZQM-UHFFFAOYSA-N 0.000 description 1
- DWAHMJXLIGCNPL-UHFFFAOYSA-N 8-cyclopentyl-2-(4-piperidin-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1CCCCC1 DWAHMJXLIGCNPL-UHFFFAOYSA-N 0.000 description 1
- KFJQJECINHKABS-UHFFFAOYSA-N 8-cyclopentyl-2-(4-pyrazol-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1C=CC=N1 KFJQJECINHKABS-UHFFFAOYSA-N 0.000 description 1
- SQOZTNOIWIVSAS-UHFFFAOYSA-N 8-cyclopentyl-2-(4-pyrrol-1-ylanilino)-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)NCC2=CN=C1NC(C=C1)=CC=C1N1C=CC=C1 SQOZTNOIWIVSAS-UHFFFAOYSA-N 0.000 description 1
- WICZYSQVQRNSED-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(3,5-dimethylpiperazin-1-yl)anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 WICZYSQVQRNSED-UHFFFAOYSA-N 0.000 description 1
- FDSJSDZDHXDORH-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(3-hydroxypiperidin-1-yl)anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1C(O)CCCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 FDSJSDZDHXDORH-UHFFFAOYSA-N 0.000 description 1
- ICXUUIZSHRHIEG-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 ICXUUIZSHRHIEG-UHFFFAOYSA-N 0.000 description 1
- FLVKGRRNMBJADU-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[2-(diethylamino)ethoxy]-3-methylanilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1=C(C)C(OCCN(CC)CC)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 FLVKGRRNMBJADU-UHFFFAOYSA-N 0.000 description 1
- CKDOVKZRKHYOSY-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CC(CCCO)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 CKDOVKZRKHYOSY-UHFFFAOYSA-N 0.000 description 1
- QIZNWJUOSUSIJM-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C1CC(N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(CNC(=O)N2C3CCCC3)C2=N1 QIZNWJUOSUSIJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101100240523 Caenorhabditis elegans nhr-19 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023408 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Human genes 0.000 description 1
- 229930194542 Keto Chemical group 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical group OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
- 101710122944 Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 1
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 101710086605 Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- ZPGVLDQXMSGLHG-UHFFFAOYSA-N [1-(4-aminophenyl)piperidin-3-yl]methanol Chemical compound C1=CC(N)=CC=C1N1CC(CO)CCC1 ZPGVLDQXMSGLHG-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940061631 citric acid acetate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- KTMGNAIGXYODKQ-VOTSOKGWSA-N ethyl (e)-2-cyano-3-ethoxyprop-2-enoate Chemical class CCO\C=C(/C#N)C(=O)OCC KTMGNAIGXYODKQ-VOTSOKGWSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SFNSLLSYNZWZQG-VQIMIIECSA-N glasdegib Chemical compound N([C@@H]1CCN([C@H](C1)C=1NC2=CC=CC=C2N=1)C)C(=O)NC1=CC=C(C#N)C=C1 SFNSLLSYNZWZQG-VQIMIIECSA-N 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- AYXLWUQMWRMNMA-UHFFFAOYSA-N methyl 2-chloro-3,5-dimethoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC(OC)=C1Cl AYXLWUQMWRMNMA-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 1
- 150000003956 methylamines Chemical group 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- QOHMWDJIBGVPIF-UHFFFAOYSA-N n',n'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- HVJYZCOPOFTFNA-UHFFFAOYSA-N n-(cyclohexylideneamino)-4-methylthiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NN=C2CCCCC2)=C1C HVJYZCOPOFTFNA-UHFFFAOYSA-N 0.000 description 1
- POWOZQCTKIJTCZ-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-2-methylsulfanyl-4-(propan-2-ylamino)pyrimidine-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CN=C(SC)N=C1NC(C)C POWOZQCTKIJTCZ-UHFFFAOYSA-N 0.000 description 1
- XIRWWHFKDDHPRC-UHFFFAOYSA-N n-[2-[4-[4-(2-aminoacetyl)piperazin-1-yl]anilino]-8-cyclopentylpyrido[4,3-d]pyrimidin-7-yl]-2,2-dimethylpropanamide Chemical compound N=1C2=C(C3CCCC3)C(NC(=O)C(C)(C)C)=NC=C2C=NC=1NC(C=C1)=CC=C1N1CCN(C(=O)CN)CC1 XIRWWHFKDDHPRC-UHFFFAOYSA-N 0.000 description 1
- SVLHZCZXLXZPOQ-UHFFFAOYSA-N n-[7-[4-(4-acetylpiperazin-1-yl)anilino]pyrimido[4,5-d]pyrimidin-2-yl]-3-methylbutanamide Chemical compound N=1C2=NC(NC(=O)CC(C)C)=NC=C2C=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 SVLHZCZXLXZPOQ-UHFFFAOYSA-N 0.000 description 1
- DKBLOBPJPMPPBJ-UHFFFAOYSA-N n-[7-[4-[3-(aminomethyl)pyrrolidin-1-yl]anilino]pyrimido[4,5-d]pyrimidin-2-yl]-3-methylbutanamide Chemical compound N=1C2=NC(NC(=O)CC(C)C)=NC=C2C=NC=1NC(C=C1)=CC=C1N1CCC(CN)C1 DKBLOBPJPMPPBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- HERMUROLWWSOJK-UHFFFAOYSA-N pyrido[3,2-d]pyrimidin-7-ol Chemical class C1=NC=NC2=CC(O)=CN=C21 HERMUROLWWSOJK-UHFFFAOYSA-N 0.000 description 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000034932 regulation of DNA biosynthetic process Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000034394 regulation of mitosis Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8670898P | 1998-05-26 | 1998-05-26 | |
US12615899P | 1999-03-25 | 1999-03-25 | |
PCT/US1999/010187 WO1999061444A2 (en) | 1998-05-26 | 1999-05-10 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000799A2 true HRP20000799A2 (en) | 2001-06-30 |
Family
ID=26775058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000799A HRP20000799A2 (en) | 1998-05-26 | 2000-11-20 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
Country Status (29)
Country | Link |
---|---|
US (1) | US7501425B1 (zh) |
EP (1) | EP1080092B1 (zh) |
JP (1) | JP2002516327A (zh) |
KR (1) | KR20010043829A (zh) |
CN (1) | CN1138778C (zh) |
AP (1) | AP2000001964A0 (zh) |
AT (1) | ATE402177T1 (zh) |
AU (1) | AU763839B2 (zh) |
BG (1) | BG104960A (zh) |
BR (1) | BR9911590A (zh) |
CA (1) | CA2329703C (zh) |
DE (1) | DE69939168D1 (zh) |
EA (1) | EA003640B1 (zh) |
EE (1) | EE200000706A (zh) |
ES (1) | ES2310039T3 (zh) |
GE (1) | GEP20033093B (zh) |
HK (1) | HK1039483A1 (zh) |
HR (1) | HRP20000799A2 (zh) |
HU (1) | HUP0102514A3 (zh) |
ID (1) | ID27589A (zh) |
IL (1) | IL139599A0 (zh) |
IS (1) | IS5687A (zh) |
NO (1) | NO20005928L (zh) |
NZ (1) | NZ508268A (zh) |
PL (1) | PL344248A1 (zh) |
SK (1) | SK17532000A3 (zh) |
TR (1) | TR200003429T2 (zh) |
WO (1) | WO1999061444A2 (zh) |
YU (1) | YU73300A (zh) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID27589A (id) | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
WO2000024744A1 (en) * | 1998-10-23 | 2000-05-04 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
CN1156477C (zh) * | 1999-10-21 | 2004-07-07 | 霍夫曼-拉罗奇有限公司 | 作为p38蛋白激酶的抑制剂的烷基氨基-取代的双环氮杂环类化合物 |
ATE353329T1 (de) | 1999-10-21 | 2007-02-15 | Hoffmann La Roche | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen |
EE200200412A (et) * | 2000-01-24 | 2003-10-15 | Warner-Lambert Company | 3-aminokinasoliin-2,4-dioon kui antibakteriaalne agens |
AP2002002586A0 (en) * | 2000-01-25 | 2002-09-30 | Warner Lambert Co | Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. |
US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
MY141144A (en) * | 2000-03-02 | 2010-03-15 | Smithkline Beecham Corp | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
IL151480A0 (en) * | 2000-03-06 | 2003-04-10 | Warner Lambert Co | 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors |
US6506749B2 (en) | 2000-08-31 | 2003-01-14 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (I) |
AU9378401A (en) * | 2000-08-31 | 2002-03-13 | Hoffmann La Roche | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
CZ20031125A3 (cs) | 2000-10-23 | 2003-10-15 | Smithkline Beecham Corporation | Nové sloučeniny |
GB0029015D0 (en) | 2000-11-28 | 2001-01-10 | Univ London | Medical device |
JP2004521118A (ja) | 2001-01-19 | 2004-07-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物およびその使用 |
HU229604B1 (en) | 2001-02-12 | 2014-02-28 | Hoffmann La Roche | 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them |
US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
MXPA03010799A (es) | 2001-05-30 | 2005-07-25 | Warner Lambert Co | Agentes antibacterianos. |
ATE314370T1 (de) * | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
PL373339A1 (en) | 2002-04-19 | 2005-08-22 | Smithkline Beecham Corporation | Novel compounds |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
DE60316581T2 (de) | 2002-08-06 | 2008-07-03 | F. Hoffmann-La Roche Ag | 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase |
US7084270B2 (en) * | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
TW200413381A (en) * | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
US7112676B2 (en) * | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
JP2006516561A (ja) * | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
EP1615928A1 (en) | 2003-04-10 | 2006-01-18 | F.Hoffmann-La Roche Ag | Pyrimido compounds |
DE10325133A1 (de) * | 2003-06-04 | 2004-12-23 | Bayer Cropscience Ag | Triazolopyrimidine |
MXPA06001098A (es) | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
DK1685131T3 (da) | 2003-11-13 | 2007-07-09 | Hoffmann La Roche | Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner |
EP1763514A2 (en) * | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
RU2007111758A (ru) | 2004-08-31 | 2008-10-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ |
CA2576818A1 (en) | 2004-08-31 | 2006-03-09 | F. Hoffmann-La Roche Ag | Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
US7479558B2 (en) | 2005-03-25 | 2009-01-20 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives |
EP1868612A4 (en) | 2005-03-25 | 2010-03-24 | Glaxo Group Ltd | NOVEL CONNECTIONS |
PE20100737A1 (es) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
PE20100741A1 (es) | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
CN101374840B (zh) | 2006-01-31 | 2011-09-28 | 霍夫曼-拉罗奇有限公司 | 7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用 |
PL2168966T3 (pl) * | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
BRPI0906598A2 (pt) | 2008-02-01 | 2015-07-07 | Takeda Pharmaceutical | Oxim derivattivos como inibidores hsp90 |
EP2376494A4 (en) * | 2008-12-12 | 2012-07-11 | Msd Kk | DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES |
EP2376493B1 (en) | 2008-12-12 | 2016-10-05 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
WO2010080712A2 (en) * | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
AU2010218781A1 (en) * | 2009-02-25 | 2011-07-28 | Msd K.K. | Pyrimidopyrimidoindazole derivative |
SA111320200B1 (ar) * | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
CA2807498C (en) * | 2010-08-05 | 2017-02-07 | Temple University-Of The Commonwealth System Of Higher Education | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
TWI548621B (zh) | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
SI2766346T1 (sl) | 2011-10-14 | 2017-05-31 | Bristol-Myers Squibb Company | Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji |
ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
WO2013055984A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
ME03300B (me) * | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
DK2872491T3 (da) * | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
SI2906551T1 (en) | 2012-10-12 | 2018-05-31 | Bristol-Myers Squibb Company | CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
CN111793068A (zh) | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
DK2986610T5 (en) * | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
US9783504B2 (en) | 2013-07-09 | 2017-10-10 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
TWI597268B (zh) | 2013-10-18 | 2017-09-01 | 衛材R&D企管股份有限公司 | 纖維母細胞受體4(fgfr4)抑制劑 |
JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
MX2016007898A (es) | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環 |
NO2760821T3 (zh) | 2014-01-31 | 2018-03-10 | ||
CN103880861B (zh) * | 2014-02-21 | 2016-02-03 | 温州医科大学 | 一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮衍生物 |
JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fxia阻害剤であるジアミドマクロ環 |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
ES2864712T3 (es) | 2015-04-14 | 2021-10-14 | Eisai R&D Man Co Ltd | Compuesto inhibidor de FGFR4 cristalino y usos del mismo |
WO2017196854A1 (en) | 2016-05-10 | 2017-11-16 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
CN107459519A (zh) * | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
KR20190075043A (ko) * | 2016-07-05 | 2019-06-28 | 더 브로드 인스티튜트, 인코퍼레이티드 | 비시클릭 우레아 키나제 억제제 및 그의 용도 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
RU2019129727A (ru) | 2017-02-28 | 2021-03-30 | Зэ Дженерал Хоспитал Корпорэйшн | Применения пиримидопиримидинонов в качестве ингибиторов sik |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
MX2023000056A (es) | 2020-07-02 | 2023-04-12 | Incyte Corp | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為jak2 v617f抑制劑之螺環內醯胺 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2949466A (en) | 1958-03-04 | 1960-08-16 | Parke Davis & Co | Pyrimidine compounds and means of producing the same |
NL6704601A (zh) | 1966-04-06 | 1967-10-09 | ||
US3912723A (en) | 1971-03-29 | 1975-10-14 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
CA1132137A (en) * | 1979-06-14 | 1982-09-21 | David S. Duch | Alkoxybenzylpyridopyrimidines, methods for their preparation, formulations thereof and their use in medicine |
US4425346A (en) | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
JPS60226882A (ja) | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
EP0278686A1 (en) * | 1987-02-07 | 1988-08-17 | The Wellcome Foundation Limited | Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof |
DK0584222T3 (da) * | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
US5679683A (en) * | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
JP2002515008A (ja) | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
EP0790997B1 (en) * | 1994-11-14 | 2000-03-22 | Warner-Lambert Company | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
JP2001509805A (ja) * | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ATE286053T1 (de) * | 1997-08-20 | 2005-01-15 | Warner Lambert Co | Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung |
JP4038624B2 (ja) | 1997-11-29 | 2008-01-30 | 日本農薬株式会社 | 縮合複素環誘導体及びその中間体並びに有害生物防除剤 |
ID27589A (id) | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
WO2000024744A1 (en) * | 1998-10-23 | 2000-05-04 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
ATE353329T1 (de) | 1999-10-21 | 2007-02-15 | Hoffmann La Roche | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen |
CN1156477C (zh) | 1999-10-21 | 2004-07-07 | 霍夫曼-拉罗奇有限公司 | 作为p38蛋白激酶的抑制剂的烷基氨基-取代的双环氮杂环类化合物 |
MY141144A (en) | 2000-03-02 | 2010-03-15 | Smithkline Beecham Corp | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
-
1999
- 1999-05-10 ID IDW20002452A patent/ID27589A/id unknown
- 1999-05-10 DE DE69939168T patent/DE69939168D1/de not_active Expired - Fee Related
- 1999-05-10 TR TR2000/03429T patent/TR200003429T2/xx unknown
- 1999-05-10 CA CA002329703A patent/CA2329703C/en not_active Expired - Fee Related
- 1999-05-10 AU AU40734/99A patent/AU763839B2/en not_active Ceased
- 1999-05-10 GE GEAP19995700A patent/GEP20033093B/en unknown
- 1999-05-10 JP JP2000550849A patent/JP2002516327A/ja not_active Abandoned
- 1999-05-10 BR BR9911590-5A patent/BR9911590A/pt not_active Application Discontinuation
- 1999-05-10 HU HU0102514A patent/HUP0102514A3/hu unknown
- 1999-05-10 AT AT99924165T patent/ATE402177T1/de not_active IP Right Cessation
- 1999-05-10 EA EA200001171A patent/EA003640B1/ru not_active IP Right Cessation
- 1999-05-10 US US09/623,737 patent/US7501425B1/en not_active Expired - Fee Related
- 1999-05-10 PL PL99344248A patent/PL344248A1/xx not_active Application Discontinuation
- 1999-05-10 EP EP99924165A patent/EP1080092B1/en not_active Expired - Lifetime
- 1999-05-10 KR KR1020007013279A patent/KR20010043829A/ko not_active Application Discontinuation
- 1999-05-10 CN CNB998065587A patent/CN1138778C/zh not_active Expired - Fee Related
- 1999-05-10 NZ NZ508268A patent/NZ508268A/xx unknown
- 1999-05-10 AP APAP/P/2000/001964A patent/AP2000001964A0/en unknown
- 1999-05-10 EE EEP200000706A patent/EE200000706A/xx unknown
- 1999-05-10 IL IL13959999A patent/IL139599A0/xx unknown
- 1999-05-10 WO PCT/US1999/010187 patent/WO1999061444A2/en not_active Application Discontinuation
- 1999-05-10 SK SK1753-2000A patent/SK17532000A3/sk unknown
- 1999-05-10 YU YU73300A patent/YU73300A/sh unknown
- 1999-05-10 ES ES99924165T patent/ES2310039T3/es not_active Expired - Lifetime
-
2000
- 2000-10-27 IS IS5687A patent/IS5687A/is unknown
- 2000-11-17 BG BG104960A patent/BG104960A/xx unknown
- 2000-11-20 HR HR20000799A patent/HRP20000799A2/hr not_active Application Discontinuation
- 2000-11-23 NO NO20005928A patent/NO20005928L/no not_active Application Discontinuation
-
2001
- 2001-11-08 HK HK01107828A patent/HK1039483A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000799A2 (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
EP0964864B1 (en) | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation | |
US20040044012A1 (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
US5945422A (en) | N-oxides of amino containing pyrido 2,3-D! pyrimidines | |
ES2274526T3 (es) | Pirido(2,3-d)pirimidinas para inhibir la proliferacion celular mediada por tirosinaquinasa. | |
KR100421156B1 (ko) | 단백질티로신키나제매개세포증식을억제하기위한피리도[2,3-d]피리미딘 | |
US20070049600A1 (en) | Pteridinones as kinase inhibitors | |
CZ286160B6 (cs) | 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi | |
El-Zahar et al. | Synthesis, antitumor activity and molecular docking study of novel benzofuran-2-yl pyrazole pyrimidine derivatives | |
KR20020070520A (ko) | 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체 | |
Abd El-Salam et al. | Synthesis, Structural Characterization of Some Pyrazolo [3, 4-d] pyrimidine Derivatives as Anti-inflammatory Agents | |
EP1801112A1 (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
CZ20004246A3 (cs) | Bicyklické pyrimidiny a bicyklické 3,4- dihydropyrimidiny jako inhibitory buněčné proliferace | |
MXPA00010738A (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
OA11554A (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation. | |
ZA200006536B (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation. | |
CN116731038A (zh) | 含氮杂环化合物及其制备方法和应用 | |
CA2199964A1 (en) | 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODBI | Application refused |